| |
All
|
New-onset GCA
|
Established GCA
|
|---|
|
Gender
|
|
Female
|
22
|
5
|
17
|
|
Male
|
13
|
4
|
9
|
|
Mean age, years
|
71
|
72
|
65
|
|
Disease duration, mean in years
|
2.5 (range 0–4)
|
< 2 months
|
2.9 (range 0–8)
|
|
Disease onset
|
|
Newly diagnosed
|
9
| | |
|
Established disease
|
26
| | |
|
Visual manifestations
|
5
|
0
|
5
|
|
Jaw claudication
|
1
|
1
|
0
|
|
Arm claudication
|
3
|
1
|
2
|
|
Patients having temporal artery biopsy (TAB)
|
23
|
2
|
21
|
|
TAB positive
|
15
|
1
|
14
|
|
CRP (range) g/L
|
7.5 (1–200)
|
24 (4–200)
|
4 (1–57)
|
|
Corticosteroid dose (range) mg/day
|
5 (0–60)
|
60 (20–60)
|
5 (0–25)
|
|
Steroid sparing medications
|
|
Methotrexate
|
4
|
0
|
4
|
|
Leflunomide
|
2
|
0
|
2
|
|
Etanercept
|
1
|
0
|
1
|
- GCA giant cell arteritis, TAB temporal artery biopsy, CRP C-reactive protein
